Myeloid Leukemia Equipment & Supplies In Mali
108 equipment items found
Manufactured by:Wuhan HealthCare Biotechnology Co., Ltd. based inWuhan, CHINA
Translocations in bands 11q23.3-11q24 are associated with several human cancers, including acute lymphoid and acute myeloid leukemias (AML) and Ewing's sarcoma. ...
Manufactured by:Saladax Biomedical, Inc. based inBethlehem, PENNSYLVANIA (USA)
Targeted therapies are revolutionizing oncology. Patients with chronic myeloid leukemia treated with the tyrosine kinase inhibitors (TKI) now have life expectancies approaching that of the general population. Imatinib (Gleevec®, Gilvec®) the first TKI approved has substantial efficacy in chronic myeloid leukemia (CML) and gastrointestinal stromal ...
Manufactured by:The Menarini Group based inFlorence, ITALY
MEN1703 is a dual kinase inhibitor targeting PIM (PIM1, PIM2, PIM 3) and FLT3 kinases. FLT3 internal tandem duplication (FLT3-ITD) is one of the most common genetic lesions in acute myeloid leukemia patients (AML) and is associated with a poor prognosis. PIM kinases are thought to be one of the major drivers of the resistance phenotype to FLT3 inhibitors and their inhibition in relapsed samples ...
Manufactured by:Daiichi Sankyo Company Limited based inTokyo, JAPAN
VANFLYTA is a FLT3 inhibitor approved in Japan for the treatment of adult patients with acute myeloid leukemia (AML) that is FLT3-ITD mutation positive, including for use in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy and as maintenance monotherapy for newly diagnosed FLT3-ITD positive AML, based on the results of the ...
Manufactured by:Agilent Technologies, Inc. based inSanta Clara, CALIFORNIA (USA)
The ClearSeq AML panel targets 20 genes identified by leading researchers to be frequently mutated in acute myeloid leukemia (AML). It is designed for full coverage of target regions with multiple amplicons covering each target for greater confidence in somatic variant calling. Combined with intuitive data analysis workflows in Agilent’s SureCall software, you can now profile your myeloid ...
by:Xiamen Spacegen Co., Ltd. based inxiamen, CHINA
Detection Gene:BCR-ABL gene T315I mutation detection. Detection Significance:Detect the resistance mechanism of conventional targeted drugs in patients with chronic myeloid ...
Manufactured by:JW Pharmaceutical Corporation based inSeocho-gu, SOUTH KOREA
Active Ingredients: cyclophosphamide 50mg per 1 ...
Manufactured by:Beijing Challen Biotechnology Co., Ltd. based inDaxing District, CHINA
Our product production process strictly follows relevant standards and undergoes multiple rigorous tests to ensure product quality. We pay great attention to details and use a rigorous attitude to ensure the smooth progress of your experiment or detection. We promise fast supply, ensure timely delivery, and provide comprehensive pre-sales and after-sales services to meet your ...
by:Precipio, Inc based inNew Haven, CONNECTICUT (USA)
Precipio’s HemeScreen acute myeloid leukemia AML Panel offerings are in vitro diagnostic assays that screen for clinically actionable somatic mutations in targets of interest related to AML. This Research Use Only (RUO) assay is specifically designed to screen for mutations using High Resolution Melt Analysis in genes that are of clinical relevance: IDH1, IDH2, FLT3, KIT, CEBPA, and NPM1. ...
Manufactured by:Beijing Challen Biotechnology Co., Ltd. based inDaxing District, CHINA
50 tests/box; 100 tests/box. Detection method: flow antibody method. Scope of application: Detect the expression of CD4 in human biological specimens and provide doctors with auxiliary information for diagnosis. Testable items: Lymphocyte subpopulation detection, CD4 cell count, regulatory T cells, PD-1, blast cells of acute T lymphoblastic leukemia, tumor cells of mature T cell lymphoma, ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
DSP-5336 is a small molecule inhibitor against the binding of menin and mixed-lineage leukemia (MLL) protein. Menin is a scaffold nuclear protein that plays various key roles in biological pathways, including cell growth regulation, cell cycle control, genomic stability, bone development, and hematopoiesis.26,27 Binding of menin to MLL fusion and wildtype proteins leads to the upregulation of ...
by:Alfa Cytology based inU.S. VIRGIN ISLANDS
Axl-IN-7 (Chemie 22) is a potent AXL inhibitor. Axl-IN-7 can be used to study Axl-related diseases, such as cancer (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer and glioma), kidney disease, immune system disease and cardiovascular disease. ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-1287 is an investigational oral CDK9 inhibitor that has shown favorable oral bioavailability in preclinical models. TP-1287 is enzymatically cleaved, yielding the active moiety, a potent inhibitor of CDK9.35 Inhibiting CDK9 is thought to downregulate the transcription of target genes, including MCL-1, reducing leukemic blast viability in MCL-1–dependent hematologic malignancies, and ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK003: A phase 1 study evaluating NK cells as a treatment for patients with relapse and refractory acute myeloid leukemia (AML). This study was designed based on promising clinical proof-of-concept data from two studies, one at MD Anderson Cancer Center and one at HCPA in ...
Manufactured by:Asuragen, Inc. based inAustin, TEXAS (USA)
Assessing complete molecular response requires the highest possible assay sensitivity. The FDA-cleared QuantideX® qPCR BCR-ABL IS Kit takes chronic myeloid leukemia (CML) monitoring to a new level of sensitivity – 0.002% IS (MR4.7). It’s a qPCR-based in vitro Diagnostic test for the quantitation of BCR-ABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) ...
Manufactured by:Senti Biosciences based inSouth San Francisco, CALIFORNIA (USA)
Pursuing an Unmet Need in the Treatment of AML - SENTI-202 is designed to target and eliminate acute myeloid leukemia cells while sparing healthy bone marrow. Our vision is a potential medicine that does not rely on an invasive bone marrow ...
Manufactured by:LAVA Therapeutics N.V. based inUtrecht, NETHERLANDS
Our lead program, LAVA-051, is a unique, humanized gamma-delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). We have achieved preclinical proof-of-concept with LAVA-051 by demonstrating efficacy and safety in a variety of preclinical models. LAVA-051 uniquely activates both Vγ9Vδ2 T cells as ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
VOR33 is our lead eHSC product candidate designed to replace the standard of care in transplant settings. Once the VOR33 cells have engrafted, we believe that patients can be treated with anti-CD33 therapies, such as Mylotarg or VCAR33, with limited on-target toxicity, leading to durable anti-tumor activity and potential cures. In preclinical studies, we have observed that the removal of CD33 ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK002: A phase 2 clinical study evaluating haplo-identical NK cells to prevent post-transplant relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This study was designed based on promising clinical proof-of-concept data from MD Anderson Cancer Center. The phase 2 trial for K-NK002 will be conducted in collaboration with the Bone Marrow Transplant Clinical ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
CD123 is expressed on multiple malignancies including BPDCN, AML, certain myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), B-cell acute lymphoid leukemia (B-ALL), hairy cell leukemia, and Hodgkin’s and certain non-Hodgkin’s lymphomas. In addition to expression on tumor bulk, CD123 expression has been reported on the cancer stem cells ...